Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)

NCT03213002 is registered in ClinicalTrials.gov with Northwell Health as lead sponsor.

NCT NCT03213002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03213002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed Glioblastoma (GBM)
Lead sponsor
Northwell Health
Phase
Phase 1/2
Overall status
Recruiting
Start date
June 13, 2017
Completion date
June 30, 2029
Enrollment
67 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain cancer, brain tumor, brain tumor adult, brain tumor, primary, cancer, glioblastoma, glioblastoma multiforme (gbm), glioblastoma, adult, glioma of brain